Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s43440-021-00224-4.pdf
Reference38 articles.
1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937–42.
2. ADA. Standards of medical care in diabetes. 2019;42:21
3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
4. Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, et al. Empagliflozin in women with type 2 diabetes and cardiovascular disease—an analysis of EMPA-REG OUTCOME(R). Diabetologia. 2018;61:1522–7.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives;Critical Reviews in Clinical Laboratory Sciences;2024-06-07
2. Glukagon Benzeri Peptit -1 Reseptör Agonisti Liraglutidin Sıçan Detrüsor Kas Kasılma Yanıtı Üzerine Etkisi;Turkish Journal of Diabetes and Obesity;2024-04-29
3. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress;Free Radical Biology and Medicine;2024-03
4. Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?;Journal of Basic and Clinical Physiology and Pharmacology;2024-01-01
5. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists;Antioxidants;2023-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3